Australia is gain access to a groundbreaking treatment for excess weight: Retatrutide. This dual agonist – targeting on both GLP-1 and GIP receptors – demonstrates promising outcomes in international research, indicating meaningful reductions in BMI. While regulatory clearance hasn't occurred with Australian regulators, many Australians struggl